{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:33:44Z","timestamp":1767854024946,"version":"3.49.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Low Genit Tract Dis"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>The aim of the study was to compare the rate of high-risk human papillomavirus (HR-HPV) genotypes in vaccinated (Gardasil [quadrivalent]) and unvaccinated cohorts of young women.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods<\/jats:title>\n            <jats:p>This is a retrospective, cross-sectional study, consisting of the comparison of the prevalence of HPV 16, 18, and other HR genotypes in 2183 women younger than 25 years, according to their birth year (born &gt;1994 [mostly vaccinated &lt;13 years]; born 1992\u20131994 [vaccinated at 17 years]; born &lt;1992 [not vaccinated\/vaccinated &gt;17 years]), in a private laboratory.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The rates of HPV 16, 18, 16\/18, and others in the cohort born before 1992 (n = 331) were 6.3%, 1.5%, 7.9%, and 31.7%. In those born 1992\u20131994 (n = 901), the rates were 3.3%, 0.4%, 3.6%, and 32.5%; in the ones born after 1994 (n = 951), the rates were 0.7%, 0.2%, 0.9%, and 33.2%, respectively.<\/jats:p>\n            <jats:p>There were no changes in the relative risk (RR) of HR-HPV infection by genotypes other than HPV 16\/18 in any cohort.<\/jats:p>\n            <jats:p>The RR was significantly reduced in the cohort born after 1994 for HPV 16 (0.12 [0.050\u20130.270], <jats:italic toggle=\"yes\">p<\/jats:italic> &lt; .0001), HPV 18 (0.14 [0.027\u20130.714], <jats:italic toggle=\"yes\">p<\/jats:italic> = .02), and HPV 16\/18 (0.12 [0.057\u20130.254], <jats:italic toggle=\"yes\">p<\/jats:italic> &lt; .0001).<\/jats:p>\n            <jats:p>In those born 1992\u20131994, there was a nearly significant reduction in the RR of HPV 18 infection (0.29 [0.079\u20131.09], <jats:italic toggle=\"yes\">p<\/jats:italic> = .07); the reduction was significant for HPV 16 (0.52 [0.305\u20130.904], <jats:italic toggle=\"yes\">p<\/jats:italic> = .02) and HPV 16\/18 (0.45 [0.274\u20130.747], <jats:italic toggle=\"yes\">p<\/jats:italic> = .0018).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Young women vaccinated before 13 years had a nearly 90% risk reduction of HPV 16\/18, whereas if vaccinated at 17 years, the decrease was of 50%. There was no impact in the nonvaccine genotypes.<\/jats:p>\n            <jats:p>Our data highlight the importance of vaccinating at young age and of introducing vaccines covering more HR genotypes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/lgt.0000000000000564","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T02:13:41Z","timestamp":1597371221000},"page":"363-366","source":"Crossref","is-referenced-by-count":7,"title":["Impact of a High Coverage Vaccination Rate on Human Papillomavirus Infection Prevalence in Young Women: A Cross-sectional Study"],"prefix":"10.1097","volume":"24","author":[{"given":"Concei\u00e7\u00e3o","family":"Saldanha","sequence":"first","affiliation":[{"name":"LAP \u2013 A Unilabs Company, Porto, Portugal"}]},{"given":"Pedro","family":"Vieira-Baptista","sequence":"additional","affiliation":[]},{"given":"Mariana","family":"Costa","sequence":"additional","affiliation":[{"name":"LAP \u2013 A Unilabs Company, Porto, Portugal"}]},{"given":"Ana Rita","family":"Silva","sequence":"additional","affiliation":[{"name":"LAP \u2013 A Unilabs Company, Porto, Portugal"}]},{"given":"Miguel","family":"Pic\u00e3o","sequence":"additional","affiliation":[{"name":"LAP \u2013 A Unilabs Company, Porto, Portugal"}]},{"given":"Carlos","family":"Sousa","sequence":"additional","affiliation":[{"name":"LAP \u2013 A Unilabs Company, Porto, Portugal"}]}],"member":"276","published-online":{"date-parts":[[2020,8,12]]},"reference":[{"key":"bib1-20230821","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ogc.2018.09.007","article-title":"(At Least) Once in Her Lifetime: Global Cervical Cancer Prevention","volume":"46","year":"2019","journal-title":"Obstet Gynecol Clin North Am"},{"key":"bib3-20230821","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ypmed.2015.01.034","article-title":"Changes in cervical cancer incidence following the introduction of organized screening in Italy","volume":"75","year":"2015","journal-title":"Prev Med"},{"key":"bib4-20230821","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1002\/ijc.30579","article-title":"Eurogin 2016 Roadmap: how HPV knowledge is changing screening practice","volume":"140","year":"2017","journal-title":"Int J Cancer"},{"key":"bib5-20230821","first-page":"CD009069","article-title":"Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors","volume":"5","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"bib6-20230821","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.vaccine.2015.01.084","article-title":"Reduction in HPV 16\/18-associated high grade cervical lesions following HPV vaccine introduction in the United States \u2013 2008\u20132012","volume":"33","year":"2015","journal-title":"Vaccine"},{"key":"bib7-20230821","doi-asserted-by":"crossref","first-page":"337","DOI":"10.15585\/mmwr.mm6815a1","article-title":"Estimated number of cases of high-grade cervical lesions diagnosed among women \u2014 United States, 2008 and 2016","volume":"68","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"bib8-20230821","doi-asserted-by":"crossref","first-page":"e91905","DOI":"10.1371\/journal.pone.0091905","article-title":"A promising DNA methylation signature for the triage of high-risk human papillomavirus DNA-positive women","volume":"9","year":"2014","journal-title":"PLoS One"},{"key":"bib9-20230821","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/LGT.0000000000000452","article-title":"Immediate loop electrode excisional procedure for high-grade cervical cytology","volume":"23","year":"2019","journal-title":"J Low Genit Tract Dis"},{"key":"bib10-20230821","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.vaccine.2018.11.075","article-title":"Age-specific HPV prevalence among 116,052 women in Australia's renewed cervical screening program: a new tool for monitoring vaccine impact","volume":"37","year":"2019","journal-title":"Vaccine"},{"key":"bib11-20230821","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygyno.2017.04.004","article-title":"HPV vaccines \u2013 a review of the first decade","volume":"146","year":"2017","journal-title":"Gynecol Oncol"},{"key":"bib12-20230821","first-page":"1700737","article-title":"The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?","volume":"23","year":"2018","journal-title":"Euro Surveill"},{"key":"bib14-20230821","first-page":"8","article-title":"Changing of the anti-HPV vaccination schedule: risks of a premature decision","volume":"8","year":"2014","journal-title":"Acta Obstet Ginecol Port"},{"key":"bib15-20230821","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1097\/IGC.0b013e31821dd3b2","article-title":"Prevalence of human papillomavirus infection in women in Portugal the CLEOPATRE Portugal study","volume":"21","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"bib16-20230821","first-page":"8","article-title":"High-Risk human papillomavirus genotype distribution in the Northern region of Portugal: data from regional cervical cancer screening program","volume":"1","year":"2019","journal-title":"Papillomavirus Res"},{"key":"bib17-20230821","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1128\/JCM.03386-12","article-title":"Development and characterization of the cobas human papillomavirus test","volume":"51","year":"2013","journal-title":"J Clin Microbiol"},{"key":"bib18-20230821","first-page":"43","article-title":"The Abbott Realtime High Risk HPV test is a clinically validated human papillomavirus assay for triage in the referral population and use in primary cervical cancer screening in women 30 years and older: A review of validation studies","volume":"22","year":"2013","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"key":"bib19-20230821","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2159-8290.CD-11-0131","article-title":"Prevention of persistent human papillomavirus infection by an HPV16\/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica","volume":"1","year":"2011","journal-title":"Cancer Discov"},{"key":"bib20-20230821","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1473-3099(12)70187-1","article-title":"Cross-protective efficacy of two human papillomavirus vaccines: A systematic review and meta-analysis","volume":"12","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"bib21-20230821","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/infdis\/jiy249","article-title":"The impact of the national HPV vaccination program in England using the bivalent HPV vaccine: surveillance of type-specific HPV in young females, 2010\u20132016","volume":"218","year":"2018","journal-title":"J Infect Dis"},{"key":"bib22-20230821","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/infdis\/jiy516","article-title":"Bivalent human papillomavirus vaccine effectiveness in a japanese population: high vaccine-type\u2013specific effectiveness and evidence of cross-protection","volume":"219","year":"2019","journal-title":"J Infect Dis"},{"key":"bib23-20230821","doi-asserted-by":"crossref","first-page":"101593","DOI":"10.1016\/j.canep.2019.101593","article-title":"Effectiveness of bivalent and quadrivalent human papillomavirus vaccination in Luxembourg","volume":"63","year":"2019","journal-title":"Cancer Epidemiol"},{"key":"bib24-20230821","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.pvr.2016.02.003","article-title":"HPV distribution in cervical cancer in Portugal. A retrospective study from 1928 to 2005","volume":"2","year":"2016","journal-title":"Papillomavirus Res"},{"key":"bib25-20230821","doi-asserted-by":"crossref","first-page":"e20151968","DOI":"10.1542\/peds.2015-1968","article-title":"Prevalence of HPV after introduction of the vaccination program in the United States","volume":"137","year":"2016","journal-title":"Pediatrics"},{"key":"bib26-20230821","first-page":"e01120","article-title":"Alinity m HR HPV assay fulfills criteria for human papillomavirus test requirements in cervical cancer screening settings","volume":"58","year":"2019","journal-title":"J Clin Microbiol"}],"container-title":["Journal of Lower Genital Tract Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/LGT.0000000000000564","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T20:09:03Z","timestamp":1692648543000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/LGT.0000000000000564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,12]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/lgt.0000000000000564","relation":{},"ISSN":["1526-0976"],"issn-type":[{"value":"1526-0976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,12]]}}}